Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Thurner, EM; Krenn-Pilko, S; Langsenlehner, U; Stojakovic, T; Pichler, M; Gerger, A; Kapp, KS; Langsenlehner, T.
The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Eur J Cancer. 2015; 51(5):610-619
Doi: 10.1016/j.ejca.2015.01.002
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Langsenlehner Tanja
- Thurner Eva-Maria
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Kapp Karin S.
- Krenn-Pilko Sabine
- Langsenlehner Uwe
- Pichler Martin
- Stojakovic Tatjana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- C-reactive protein (CRP) is a sensitive marker of inflammation that has been linked with prognosis in various solid tumours. In the present study, we analysed the prognostic relevance of elevated plasma CRP levels in prostate cancer patients treated with radiotherapy. A total of 261 prostate cancer patients treated with 3D-conformal radiotherapy were evaluated retrospectively. Cancer specific survival (CSS), overall survival (OS) and clinical disease-free survival (DFS) were assessed using Kaplan-Meier analysis. To evaluate the independent prognostic significance of CRP plasma levels, multivariate Cox regression models were applied. The median follow-time was 80months. Applying receiver operating characteristics (ROC) analysis, the optimal cut-off level for the plasma CRP was 8.6mgl(-1). An elevated CRP level was associated with decreased CSS in univariate (hazard ratio (HR) 3.36, 95% confidence interval (CI) 1.42-7.91; p=0.006) and multivariate analysis (HR 4.31, 95% CI 1.22-15.1; p=0.023). Furthermore, a significant association with OS was detected in univariate (HR 2.69, 95% CI 1.57-4.59; p<0.001) and multivariate analyses (HR 3.24, 95% CI 1.84-5.71, p<0.001). Multivariate analysis also showed a significant association between plasma CRP and clinical DFS (HR 2.07, 95% CI 1.02-4.17; p=0.043). In the present study, an elevated plasma CRP (⩾8.6mgl(-1)) has been identified as a prognostic factor for poor CSS, OS and DFS in prostate cancer patients undergoing radiotherapy. The association between elevated CRP levels and poor prognosis was independent of other measures of prognosis such as tumour stage, Gleason grading and prostate specific antigen (PSA) level at diagnosis. If confirmed by additional studies, our findings may contribute to future individual risk assessment in prostate cancer patients. Copyright © 2015 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Area Under Curve -
- Biomarkers, Tumor - blood
- C-Reactive Protein - metabolism
- Disease Progression -
- Disease-Free Survival -
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Multivariate Analysis -
- Proportional Hazards Models -
- Prostatic Neoplasms - blood
- Prostatic Neoplasms - mortality
- Prostatic Neoplasms - radiotherapy
- ROC Curve -
- Radiotherapy, Conformal - adverse effects
- Radiotherapy, Conformal - mortality
- Retrospective Studies -
- Risk Factors -
- Time Factors -
- Treatment Outcome -
- Up-Regulation -
- Find related publications in this database (Keywords)
- Prostate cancer
- Inflammation
- Prognosis
- Radiotherapy
- C-reactive protein